Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects
Latest Information Update: 10 Sep 2023
At a glance
- Drugs GSK 1034702 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 27 May 2009 New trial record